Literature DB >> 26893382

The prognostic value of metastatic lymph node number and ratio in oesophageal squamous cell carcinoma patients with or without neoadjuvant chemoradiation.

Hung-Che Chien1, Hui-Shan Chen2, Shiao-Chi Wu2, Po-Kuei Hsu3, Chao-Yu Liu4, Bing-Yen Wang5, Chih-Hsun Shih6, Chia-Chuan Liu6.   

Abstract

OBJECTIVES: We aim to evaluate the prognostic value of metastatic lymph node number (MLN) and ratio (MLR) in oesophageal squamous cell carcinoma (OSCC) patients with or without neoadjuvant chemoradiation.
METHODS: Two thousand one hundred and fifty-one OSCC patients receiving oesophagectomy with (n = 850) or without (n = 1301) neoadjuvant chemoradiation were included. The MLN was categorized into 0 (N0), 1-2 (N1), 3-6 (N2) and more than 7 (N3); the MLR was categorized into 0, 0-0.2 and >0.2. The prognostic value was evaluated with survival analysis using the Cox proportional hazards regression model and the Kaplan-Meier method.
RESULTS: In patients without neoadjuvant chemoradiation, the 3-year overall survival rates were 54.8, 34.4, 21.8 and 6.5% with MLN = 0, 1-2, 3-6 and more than 7, respectively (P < 0.001). The 3-year overall survival rates were 54.7, 31.2 and 14.2% with MLR = 0, 0-0.2 and more than 0.2, respectively (P < 0.001). In patients with neoadjuvant chemoradiation, the 3-year overall survival rates were 49.0, 28.4, 12.5 and 0.0% with MLN = 0, 1-2, 3-6 and more than 7, respectively (P < 0.001). However, the survival curves of MLN = 3-6 and MLN ≥7 overlapped on the Kaplan-Meier plots. In contrast, MLR demonstrated good ability to show the survival differences on the Kaplan-Meier plots. The 3-year overall survival rates were 48.9, 27.3 and 0.0% with MLR = 0, 0-0.2 and more than 0.2, respectively (P < 0.001).
CONCLUSIONS: Both MLN and MLR were significant prognostic factors in OSCC patients regardless of neoadjuvant chemoradiation. But in patients with neoadjuvant chemoradiation, the survival rates were similar between ypN2 and ypN3 patients, suggesting that there was no necessity of separating patients into ypN2 and ypN3 stages.
© The Author 2016. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Entities:  

Keywords:  Lymph node; Oesophageal cancer; Prognosis

Mesh:

Year:  2016        PMID: 26893382     DOI: 10.1093/ejcts/ezw016

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  3 in total

1.  Neoadjuvant therapy in relation to lymphadenectomy and resection margins during surgery for oesophageal cancer.

Authors:  Joonas H Kauppila; Karl Wahlin; Pernilla Lagergren; Jesper Lagergren
Journal:  Sci Rep       Date:  2018-01-11       Impact factor: 4.379

2.  What are the independent prognostic factors in patients undergoing esophagectomy for esophageal cancer?

Authors:  Sermin Alcan; Makbule Ergin; Hakan Keskin; Abdullah Erdoğan
Journal:  Turk Gogus Kalp Damar Cerrahisi Derg       Date:  2022-01-28       Impact factor: 0.332

3.  Right Compared With Left Thoracic Approach Esophagectomy for Patients With Middle Esophageal Squamous Cell Carcinoma.

Authors:  Yan Zheng; Yin Li; Xianben Liu; Ruixiang Zhang; Haibo Sun; Wenqun Xing
Journal:  Front Oncol       Date:  2020-10-26       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.